Quince Therapeutics, Inc. (IRLA) Cash Flow Statement
Quince Therapeutics, Inc. (IRLA) generated -$46.9M of operating cash flow over the twelve months to 2026-06-30, spent $78000 on capital expenditure and had free cash flow of -$47.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRLAQuince Therapeutics, Inc.Follow IRLA — free
—
Price chart with a free account
- Market cap
- 33.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -33.3 | -50.8 | -62.9 | -44.0 | -18.3 | -31.9 | -41.4 | -46.9 | |
| Capital expenditure | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.3 | 0.4 | -0.1 | |
| Free cash flow | -33.3 | -50.9 | -63.1 | -44.2 | -18.5 | -32.2 | -41.8 | -47.0 | |
| Stock-based compensation | 2.1 | 14.5 | 29.9 | 16.6 | 5.2 | 4.7 | 5.1 | — |
USD millions · SEC XBRL
Quince Therapeutics, Inc. — questions
- What is Quince Therapeutics, Inc.'s operating cash flow?
- -$46.9M over the twelve months to 2026-06-30.
- How much does Quince Therapeutics, Inc. spend on capital expenditure?
- $78000 over the twelve months to 2026-06-30.
- What is Quince Therapeutics, Inc.'s free cash flow?
- -$47.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Quince Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.